TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New scan could spot rare heart disease earlier
Diagnosis Recruiting nowThis study is testing a special radioactive tracer called I-124 evuzumitide to see if it can improve diagnosis of cardiac amyloidosis, a condition where abnormal proteins build up in the heart. About 150 adults with known or suspected amyloidosis will get a PET/MRI scan after rec…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Diagnosis
Last updated May 13, 2026 16:02 UTC
-
Breakthrough trial hopes to stop rare genetic disease in its tracks
Prevention Recruiting nowThis study tests an experimental drug called acoramidis in 587 adults who carry a gene mutation for transthyretin amyloidosis (ATTR) but have no symptoms yet. The drug aims to stabilize a protein in the blood to prevent it from forming harmful plaques in the heart and nerves. If …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated May 17, 2026 01:48 UTC
-
New study tracks eplontersen safety in pregnancy and breastfeeding
Knowledge-focused Recruiting nowThis study collects information from pregnant or breastfeeding women who have taken eplontersen for transthyretin amyloidosis, and their babies. The goal is to describe any pregnancy complications or health problems in the baby up to one year old. No new treatment is given; the s…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
Massive global study tracks rare heart and nerve disease in real time
Knowledge-focused Recruiting nowThis study will follow about 1,850 people with ATTR amyloidosis, a disease that causes abnormal protein buildup in the heart and nerves. Researchers will collect information on symptoms, treatments, and outcomes over time to learn how the disease naturally progresses and how well…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC